Pregnancy Clinical Trial
Official title:
Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM)
In order to confirm the feasibility of home monitoring with Monica AN 24, a licensed
portable device for measuring fetal and maternal electrocardiogram (ECG), and the
feasibility of inpatient monitoring with Monica AN 24 in patients with Propess (a vaginal
licensed drug delivery system used for induction of labour), we will perform a pilot study
that will include 20 women in each arm.
Feasibility of monitoring with Monica AN 24 both in hospital and at home will be confirmed
in a pilot study. The success will be defined as at least 10 minutes of continuous
satisfactory trace in any given hour in at least 80% of the patient.
A main study will then be conducted to assess the feasibility and acceptability of the
Propess and Monica AN24package of care for women undergoing induction of labour.
The research questions are:
1. Is outpatient induction with continuous monitoring technically feasible?
2. Does the Propess and Monica AN24 care package of care provide adequate clinical
information in line with the UK National Institute of Clinical Evidence (NICE)
Guideline for Induction of labour?
3. Is outpatient induction a concept that appeals to women?
4. What do women consider to be the advantages and disadvantages of this package of care?
5. What would women consider to be positive and/or negative outcome in future clinical
trials of outpatient induction?
6. Do fetuses with abnormal electrocardiogram (ECG) patterns have evidence of
subclinically impaired cardiac function (feasibility study)?
7. Do elevated concentrations of white blood cell components in the umbilical cord blood
at birth influence fetal electrocardiogram (feasibility study)?
Inclusion criteria
Women with singleton pregnancy and cephalic presentation booked for induction of labour with
unfavourable cervix (Bishop score <6) and normal pre-induction fetal monitoring.
Low risk women in the context of this study include:
- Uncomplicated pregnancy requiring induction of labour after completed 37 weeks of of
pregnancy with normal fetal assessment including:
1. Social inductions/maternal requests
2. Induction of labour for symphysis pubic dysfunction
3. Obstetric Cholestasis
4. Nonspecific Proteinuria (without any other medical problems)
- Parity < 4
- Intact membranes at study entry
- Living within a reasonable distance from the hospital (i.e., not more than
approximately 60 minutes driving time)
- Caregiver present at all times while at home
- Easy access to a safe method of transport for return to hospital
- Easy access to a telephone (either land line or mobile with good service)
- Agrees to remove the pessary herself following instructions in the patient leaflet
- Written informed consent
Exclusion criteria
- Previous caesarean section
- Abnormal preinduction Cradiotocogram (CTG)
- Multiple pregnancy
- Fetal malformation or chromosomal abnormality
- Maternal age less than 18 years
- Contraindication to Propess induction
- Breech Presentation
- Foetal growth restriction
- Hypertension
- All Diabetics
Recruitment
In Liverpool Women's Hospital, women who have completed 37 weeks of Pregnancy and require
induction of labour (as per inclusion/exclusion criteria above) while attending Antenatal
clinic, delivery suite or the Obstetric Assessment Unit are offered management options.
Women who have normal cardiotocogram (CTG), normal amniotic fluid volume and cephalic
presentation confirmed by ultrasound, and who decide to have induction of labour will be
approached by one of the investigators. The participant information sheet will be given to
the woman, and participation in the study offered.
Women who accept participation will be approached again when admitted to the Induction Suite
1-3 days later. Women who labour spontaneously before induction day will be managed
according to the standard hospital protocol and will not be asked to take part in the study.
On admission to the Induction Suite the woman will be asked to sign the informed consent
form and the eligibility of consenting women will be confirmed.
Study progress
Women who sign a consent form will have a Monica AN24 fetal monitor attached to the abdomen.
Women will then follow the standard clinical protocol which includes:
- 30 minutes of fetal heart rate monitoring (FHR). This must be reassuring to continue
with the study;
- Prescription and administration of Propess
- A further 1 hour of FHR monitoring with the woman in a recumbent position in hospital
If remote FHR monitoring cannot be established during initial assessment in the hospital,
women will remain in hospital. If the in-hospital FHR signal is satisfactory, fetal
monitoring will continue to be performed with Monica AN24 throughout her labour induction.
If at any point the signal is deemed inadequate, standard CTG monitoring will be commenced.
Women will be invited to complete a semi-structured diary throughout the outpatient episode
of care. The woman's main supporter during labour (partner, mother, or friend) will also be
invited to add comments in the diary. The diary will be collected on admission to hospital
and placed in an opaque envelope. The diary will be collected by the Qualitative Team and
will not be read by the clinicians/researchers involved in the clinical care.
Women who meet all of the inclusion and none of the exclusion criteria and with a
satisfactory in-hospital Monica AN24 signal will be taken through the instruction leaflets
for the AN24 and Propess. If they are comfortable with both sets of instructions and the
staff member believes they understand the study and how to handle an emergency situation,
they will be allowed home. They will be advised that in case of research staff observing a
suboptimal/non-reassuring fetal heart rate signal, they will be contacted by phone to come
back to the hospital. Participating women will also be provided with a specially enabled
mobile phone for the duration of their involvement with the study.
The patient leaflets provided to women who are deemed suitable for home monitoring will
include instructions to contact hospital staff and come back to the hospital in case of:
1. vaginal bleeding
2. painful uterine contractions requiring pain relief
3. rhythmic, firm, uterine contractions occurring at a frequency of ≥ 3 in 10 minutes and
lasting 45 seconds or more
4. rupture of membranes
5. Pessary falling out
Women will be provided with the contact number for the Induction Suite (staffed 24/7), and
they may contact the Induction Suite staff by telephone for reassurance at any time.
The Monica AN24 monitoring will upload data to the central data base every 30 seconds via
Bluetooth technology. The fetal heart rate and uterine activity pattern will be displayed on
the PC monitor situated on the Induction Suite. This will be reviewed periodically by an
experienced midwife as per standard hospital practice for women undergoing cervical
ripening.
Women will be told to return to the hospital in case of:
1. Evidence of uterine hypertonus defined as a single contraction with duration of at
least 2 minutes
2. Evidence of uterine tachysystole defined as at least 6 contractions in 10 minutes for 2
consecutive 10 minute periods
3. Non reassuring/pathological fetal heart rate (FHR)
4. In case of regular uterine contractions (at least 3 in 10 minutes) the patient will be
contacted by the midwife and asked if the contractions are painful. If the patient
refers the contractions as non painful, home monitoring will be continued.
Whilst the participant is at home, should a situation arise that the staff believes requires
removal of the pessary (Propess), they will telephone the participant and instruct her to
remove and dispose of the insert, and request that she should immediately return to the
hospital. The staff member evaluating the situation will also determine whether emergency
transport is required, i.e., ambulance, or whether car/taxi is acceptable.
At 24 hours, assuming none of the above reasons for returning to hospital has occurred;
women will be asked to return to hospital for removal of pessary and further assessment.
Further management will be according to the standard hospital protocol for failed induction.
Provided that the FHR signal from the Monica AN24 device is adequate, the device will be
used for monitoring throughout the first stage of labour. In the second stage of labour a
standard cardiotocogram (CTG) monitoring will be added.
If at any point of the labour the signal is considered inadequate, standard cardiotocogram
(CTG) monitoring will be provided.
After birth, cord blood will be collected for analysis of lactates, cardiac enzymes,
interleukin-6 (IL-6) and reactive protein C. These results will not be disclosed to the
clinicians and will not influence subsequent management. Women will also be asked to give
consent (optional) for one neonatal electrocardiogram (ECG) recording before hospital
discharge if feasible.
Women will also be asked to participate in a face to face interview after birth to determine
their views on the outpatient care. This interview will be arranged by a member of the
Qualitative Team after discharge from hospital and take place either at home or at hospital
depending on the woman's wishes.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |